#USA #Irvine #PeproMene Bio #PMB-CT01 #B-cell Lymphomas

PeproMene Bio's Presentation Highlights Breakthrough in CAR T-Cell Therapy

In a significant advancement for cancer treatment, PeproMene Bio, Inc. has announced that its updated clinical findings on PMB-CT01, an innovative CAR T-cell therapy focused on B-cell activating factor receptor (BAFF-R), will be presented orally at the upcoming 2026 Congress of the European Hematology Association (EHA). This highlights the company’s commitment to developing cutting-edge solutions for patients with B-cell lymphomas, particularly for those facing treatment failure after conventional therapies like CD19 CAR T-cell therapy.

Clinical Study Insights

Conducted in Irvine, California, the ongoing Phase 1 study of PMB-CT01 has shown promising results, especially in patients diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). From the initial cohort of nine patients, the treatment has revealed a notable safety profile with zero dose-limiting toxicities reported. Notably, no patients experienced severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), complications frequently observed in CAR T-cell therapies.

Impressively, 78% of the participants (seven out of nine) have achieved complete responses (CR) to the therapy. As the study progressed, the data indicated that all responses remained durable, with the longest ongoing response observed extending beyond three years, pointing towards a potential breakthrough in managing aggressive forms of lymphoma. Additionally, patients who responded favorably also reached minimal residual disease (MRD)-negative status, signifying the absence of detectable cancer cells, which is a significant achievement for ongoing cancer treatment strategies.

Expanding Treatment Options

In an effort to expand treatment avenues for other types of B-cell malignancies, PeproMene has begun enrolling participants into new cohorts to explore PMB-CT01’s effectiveness against mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma. Remarkably, the first patient treated in this new phase, who had a transformed follicular lymphoma (tFL) and had previously experienced failure with CD19 CAR T therapy, also achieved complete response during their initial assessment. Given that tFL is known for its aggressive nature and limited treatment alternatives, this finding underscores the potential significance of BAFF-R as a target in CAR T-cell therapy.

Industry Perspectives

Larry W. Kwak, M.D., Ph.D., the scientific founder of PeproMene Bio, articulated the pressing need for innovative treatments in this space. He highlighted that for patients whose cancer has progressed post-CD19 CAR T therapy, options currently available are scarce. The encouraging safety profile and positive response rates seen in this study, therefore, point toward BAFF-R being a promising target for future therapies and may enable broader applications within outpatient care settings for oncology.

Presentation Details

The upcoming presentation at EHA is scheduled for June 14 from 11:00 AM to 12:15 PM CEST. Dr. Larry W. Kwak will present data under the abstract titled, “Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease.” This presentation aims to further discuss the potential of PMB-CT01 to transform treatment paradigms for B-cell malignancies.

About PeproMene Bio

PeproMene Bio, Inc., a biotechnology firm based in Irvine, California, is focused on developing innovative therapies targeting cancer and immune disorders. Their commitment to discovering new treatments, combined with the recent advances in PMB-CT01, positions them as leaders in the field of CAR T-cell therapies. For more details on their revolutionary research, individuals can visit PeproMene Bio's website.

As the medical community awaits the oral presentation at EHA 2026, the ongoing results from PeproMene Bio exemplify the promising avenues that lie ahead in the fight against challenging B-cell lymphomas.